Mankind Pharma IPO

Should I Invest?

Complete Offer for Sale (OFS) of 40,058,844 Equity Shares.

Face value of each equity share is Rs 1

Subscription Date - Apr 25, 2023 to Apr 27, 2023

Subscription Price - ₹1026 to ₹1080 per share

Listing Date - May 8, 2023

Min Lot Size - 13 Share

Min  Investment - ₹14,040

Mr. Ramesh Juneja,  Mr. Rajeev Juneja,  Mrs. Sheetal Arora 

Promoters of the company

This IPO is a complete Offer For Sale (OFS)

Company will not receive any of the offer proceeds.

Fourth largest pharmaceutical company in terms of Domestic Sales in FY 2022 in India.

“Mankind” is a well-recognized brand in India

other brands “Manforce”, “PregaNews”, and “GasOfast”

Product Categories





Respiratory and Anti-diabetic


Dermatology and Gynecology

Pain/analgesics and Neuro/CNS


11,196 medical representatives and 3,195 field managers, as of March 31, 2022

23 manufacturing facilities across India

Book Running Manager

Kotak Mahindra Capital Company Limited

Axis Capital Limited

IIFL Securities Ltd

Jefferies India Private Limited

J.P. Morgan India Private Limited

KFin Technologies Limited Phone: 04067162222, 04079611000 Email: Website:

Mankind Pharma IPO  Registrar

Mankind Pharma Financials

Mankind Pharma Financials - March 31, 2022 (INR Million)

Revenue from Operations

Profit After Tax


Net Cash from Operating Activities







Should I Invest?

Mankind Pharma is in a sweat spot in terms of product portfolio and reach in India and globe

The threat of new entrant is low in case of pharma industry

Largest domestic formulation business in India with strong brand name

More Stories Across the Site

High  Dividend Paying Stocks in the USA

Should I Invest in Gold IRA for Retirement

What should I Invest in 2023 in Economic uncertainties